EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease

Avneesh Shrivastava, Sanjay Singh iD, Gunavanthi D Boorgula, Rodolfo-Amaro Galvez, Shashikant Srivastava iD

Antimicrobial Agents and Chemotherapy · 2025

DOI: 10.1128/aac.00030-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, 2025. Verfasst von Avneesh Shrivastava und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA. Hauptthemen laut MEDLINE: Mycobacterium abscessus, Quinolones, Aminophenols, Mycobacterium Infections, Nontuberculous. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institute of Allergy and Infectious Diseases, Cystic Fibrosis Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients with cystic fibrosis have dysfunctional cystic fibrosis transmembrane conductance regulator (CFTR), and this predisposes them to nontuberculous mycobacteria (NTM), including Mycobacterium abscessus (MAB) , infection. We found that one of the CFTR modulators, ivacaftor, kills MAB in a concentration-dependent manner, with killing efficacy comparable to amikacin and imipenem, drugs in guideline-based regimens. Using clinical isolates of MAB, amikacin 1/4× MIC concentration combined with ivacaftor killed 2.67 log 10 CFU/mL MAB.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium abscessusQuinolonesAminophenolsMycobacterium Infections, NontuberculousAnti-Bacterial AgentsLung DiseasesMicrobial Sensitivity TestsHumansAmikacinCystic Fibrosis Transmembrane Conductance RegulatorCystic FibrosisImipenem

Stichwörter der Autor:innen

CFTR modulatorcystic fibrosisnontuberculous mycobacteriasusceptibility

Substanzen

QuinolonesAminophenolsivacaftorAnti-Bacterial AgentsAmikacinCystic Fibrosis Transmembrane Conductance RegulatorImipenem

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
  • Department of Medicine, Section of Pulmonary and Critical Care, School of Medicine, University of Texas at Tyler, Tyler, Texas, USA.
  • Department of Cellular and Molecular Biology, University of Texas Health Science Centre at Tyler, Tyler, Texas, USA.

ORCID-Profile: Sanjay Singh, Shashikant Srivastava

Förderung

  • NIAID NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • Cystic Fibrosis Foundation

Zitieren

APA

Shrivastava, A., Singh, S., Boorgula, G. D., Galvez, R. A., & Srivastava, S. (2025). Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. https://doi.org/10.1128/aac.00030-25

Vancouver

Shrivastava A, Singh S, Boorgula GD, Galvez RA, Srivastava S. Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease. Antimicrobial Agents and Chemotherapy. 2025. doi:10.1128/aac.00030-25

BibTeX
@article{Shrivastava2025,
  author = {Shrivastava, Avneesh and Singh, Sanjay and Boorgula, Gunavanthi D and Galvez, Rodolfo-Amaro and Srivastava, Shashikant},
  title = {Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2025},
  doi = {10.1128/aac.00030-25}
}
Kostenlos starten →